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Abstract 
Donation after cardiac death (DCD) grafts experience prolonged ischemia reperfusion injury 
(IRI) leading to higher rates of delayed graft function and failure. Recent studies have 
reported protective effects of hydrogen sulfide (H2S) against IRI. Our study aims at 
improving DCD renal graft outcomes by H2S supplementation in an in-vivo murine model of 
renal transplantation (RTx) and study the underlying mechanism in an in-vitro model using 
porcine kidney proximal-tubular-epithelial cells (LLC-PK1). H2S provided survival benefit, 
improved renal graft function and decreased renal injury in recipient rats. In our in-vitro 
model of LLC-PK1 cells, H2S demonstrated an important role mediated by mitochondria in 
the pathophysiological effects of IRI by reducing depolarization of the mitochondrial 
membrane and the amount of reactive oxygen species. In the long run, these findings would 
help bridge the gap between organ demand and supply by reducing the extent of renal IRI 
and delayed graft function in DCD donors. 
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Chapter 1  
1 Introduction 
1.1 Kidney Disease 
Kidneys are one of the vital organs in our body responsible for maintaining the normal 
physiological conditions. On average, a person’s kidneys weigh around 115grams and are 
responsible for processing about 180 liters of blood to remove waste and toxic products 
such as urea and ammonium along with excess water.
1
 Being the major excretory organs 
besides the gastrointestinal tract, they also play a role in metabolic and biosynthetic 
functions such as the regulation of renin that regulates blood volume and pressure
1
, and 
red blood cell formation via erythropoietin synthesis.
1,2
    
In some individuals, the kidneys stop working optimally and this leads to chronic kidney 
disease (CKD). CKD, as defined by the National Kidney Foundation (NKF), is either 
kidney damage or decreased kidney function [as measured by decreased Glomerular 
Filtration Rate (GFR) of less than 60mL/min/1.73m
2
] for three or more months.
3
 The loss 
of kidney function is gradual and can remain undetected for a long time. Currently, there 
are 26 million American adults that have CKD and several others are at an increased 
risk.
2
 Some factors that are known to increase a person’s vulnerability to the development 
of CKD are high blood pressure/chronic hypertension, diabetes and old age.
2,3
 About 50% 
of kidney failure cases are linked to diabetes while 30% are associated with 
hypertension.
4
 Other conditions such as polycystic kidney disease, lupus, 
glomerulonephritis and malformations during embryonic development may also affect the 
kidneys leading to a greater risk of CKD.
3
  
NKF has identified and classified CKD into five different stages based on the severity of 
kidney function loss measured by decreased GFR. Progression of CKD from its mild-
asymptomatic stages to the late stages happens gradually. The final stage of CKD is 
called the End Stage Renal Disease (ESRD) and is often described as the kidney failure 
with the GFR being less than 15mL per minute per 1.73m
2
.
1
 Upon progression into this 
2 
 
stage, the patient either needs to receive regular dialysis treatments or undergo renal 
transplantation.  
1.2 Treatment Options for ESRD 
The prevalence rate for ESRD in 2012 was reported to be 1182 per million in Canada and 
has been increasing for the past few years.
5
 The ESRD patients experience a lot of 
physical conditions including but not limited to fatigue, anorexia, pain, sleep problems, 
anxiety and depression.
6
 In addition, the risk of developing cardiovascular diseases in 
patients suffering from ESRD is almost 100 times of what is expected in the average 
population.
7
 The treatment options available to the ESRD patients are summed under the 
term renal replacement therapy (RRT) and include dialysis and renal transplant.
8
 In 2012, 
about 58% of the ESRD patients were being treated with dialysis while 42% were living 
with a functional kidney transplant in Canada.
5
  
1.2.1 Dialysis: definition and types 
Dialysis, at a biochemical level, is defined as the separation of substances in solution by 
means of their unequal diffusion across a semipermeable membrane.
9
 In medical terms, it 
generally refers to the removal of wastes or toxins from the blood and restoring the 
electrolyte and fluid balance by the use of differential diffusion rates of different 
substances through a semipermeable membrane.
10
  
There are two types of dialysis – hemodialysis and peritoneal dialysis.11 Hemodialysis 
came into practice in 1960’s10 and is the most commonly used method of dialysis. It 
requires access to the patient’s circulatory system. 9,10 The blood is pumped into the 
dialyzer for filtration from the artery. Following the removal of excess fluids and waste 
products, it is pumped back into the vein. The semi-permeable membranes installed in the 
dialyzer help carry out the process of diffusion. On the other hand, peritoneal dialysis 
involves the use of peritoneum as the semi-conservative membrane that enables the 
exchange of electrolytes, fluids and waste products.
12
 The major difference between these 
two types of dialysis is that hemodialysis needs assistance of medical personnel and is 
generally carried out in designated sections of hospitals while the peritoneal dialysis can 
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be carried out at home without visiting any medical facility.
10,13
 However, both types of 
dialysis are life saving and help in improving a patient’s quality of life.14,15 
1.2.2 Advantages and disadvantages associated with dialysis 
The major advantage for dialysis treatments is zero wait times associated with the 
initiation of the procedure. When an individual is diagnosed with CKD and needs external 
assistance in the filtration of blood, immediate help is available at medical facilities upon 
physician’s recommendation. However, some disadvantages include experiencing a 
feeling of being sick following the dialysis treatment due to the drainage of energy, 
incidents of hypo/hyper-tension, muscle cramping, restless leg syndrome, anemia and 
nausea / vomiting.
16,17
 In addition, the hemodialysis treatment involves spending several 
hours three times a week at the hospital, thereby compromising the quality of life of these 
patients.
12,14
 The frequency and time of the treatments impose a lot of limitations on a 
patient’s life such as travel, ability to work and time commitment.  
1.2.3 Renal transplant  
Renal transplant is defined as the medical procedure involving the placement of the donor 
kidney into the patient suffering from ESRD.
18
 It is the treatment of choice for most 
ESRD patients and generally happens after a prolonged time of dialysis treatments due to 
the nature of the timeline involved in receiving a transplant. The process begins when the 
physician prognosis ESRD in the patient and continues until a suitable donor kidney is 
available. However, the whole process of finding a donor kidney is time consuming and 
can take up to 3-7 years from the time of placement on the waitlist to receiving a kidney 
transplant.
19,20
  
As a result of the long wait times, many ESRD patients who do not have a  living donor 
available, die waiting for a donor organ. According to the United States Renal Data 
System, 4270 patients died in the year 2014 while waiting for a renal transplant and 
another 3617 patients became too sick to receive the transplant.
18,21
 Yet, the wait list 
continues to grow with each passing year.
21
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1.2.4 Types of organ donors 
There are two categories of organ donors that are used for renal transplantation – living 
donors and deceased/cadaveric donors.
8
 The ideal group for organ donation is the living 
donors. A living donor (for renal transplantation) is an individual who donates one kidney 
to someone in need of a transplant (ESRD patient) as the donor can survive on a single 
healthy kidney. In most cases, the living donor is somehow related to the recipient and 
this helps to reduce the wait time for finding a biologically compatible donor kidney 
[based on blood group (ABO) and human leukocyte antigen (HLA) compatibility]. On the 
other hand, the organs from the deceased donors are procured after declaration of brain or 
cardiac death. Generally speaking, the growing wait times for receiving a deceased 
donor’s kidney are due to the limited number of organ donors and increased number of 
patients along with the significant number of kidneys that are deemed unsuitable for 
transplantion (discarded organs).
8
  
In 2012, a total of 17,305 kidney transplants were performed in United States which 
included 5617 kidneys from living donors and 11,535 kidneys from the deceased donor 
pool.
21
 This shows that the deceased donors contribute a larger proportion of the total 
kidney transplants performed than do the living donors. Unfortunately, kidneys donated 
by the deceased donors have a four percent higher chances of graft failure (measured by 
factors like the patient’s return to dialysis, repeat transplantation or death) in comparison 
to that from living donors.
21
   
Further, in order to meet the organ shortage, the regulations for selecting deceased donor 
kidneys for transplantation have become less stringent. Until the year 2005, the only 
acceptable deceased organ donors for renal transplantation were the ones that belonged to 
a younger age group (19 - 44 years old) who had died from brain injuries, often referred 
to as the brain dead donors or donation after brain death (DBD).
22,23
 In these cases, 
minimal injury was experienced by the donated kidneys because the blood supply to the 
kidney was intact. However, the number of organs from the brain dead donors and living 
donors were not enough to meet the organ demand in USA. 
5 
 
The other potential opportunity to meet the organ shortage was the use of donation after 
cardiac death (DCD) organs. DCD is widely accepted as an important source of organ 
procurement in other developed countries like United Kingdom and Australia.
22
 However, 
the use of DCD organs was limited in Canada until the year 2005. The new ethical 
guidelines and policies that came into effect the same year permitted the use of DCD 
donors in Canada.
24,25
 The rate of DCD transplants has increased eight fold over the last 
two decades.
26
 The DCD donors are of two types – controlled and uncontrolled. The 
uncontrolled DCD donors are found to be dead upon arrival and have either not been 
resuscitated or resuscitated unsuccessfully.
26
 The controlled DCD organ donors are 
typically the patients in intensive care units receiving life-sustaining treatments that have 
suffered a non-recoverable brain injury. However, they fail to fulfill the criteria for the 
donation after brain death. In these cases, permission is requested from the patient’s 
family prior to the planned withdrawl of life support leading to a controlled DCD.
27
 
After the withdrawl of life-support, a period of time passes until death can be pronounced 
by cardiac arrest. This time period is highly variable during which time the organs are 
vulnerable to ischemic. Following cardiac arrest, death cannot be pronounced until five 
minutes after. Thereafter, the donor is taken to the operation room for organ procurement. 
Upon procurement, the organs are perfused with the cold storage solution until the time of 
transplantation in the recipient.
28
  
In the controlled DCD, the procured organs experience longer periods of warm ischemic 
stress during the period of time between discontinuation of life support and pronunciation 
of death. This is further exacerbated by the long periods of cold storage (cold ischemia) 
time leading to complications in the graft functioning upon transplantation.
24,28,29
 As a 
result, the risk of delayed graft function and primary non function rate are significantly 
increased in DCD renal transplants (compared to DBD organs) thereby necessitating the 
need for dialysis during the first week following transplantation.
27,30,31
  
1.2.5 Pros and cons of renal transplant  
The major determinant of patient outcomes after transplantation is the long wait time 
experienced by the patients on the waitlist before receiving the transplant. On average, a 
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person encounters 3.6 years of wait time before receiving a transplant.
21
 Due to the long 
wait times, the patients spend more years on dialysis which increases the risks of 
cardiovascular disease associated mortality in these patients.
32
 In addition, patients 
experience increased risk of infection and cancer associated with the immunosuppressive 
drugs taken for the rest of their lives in order to prevent graft rejection.
32-34
  
1.2.6 Effectiveness of renal transplant over dialysis 
Renal transplantation offers ESRD patients an improved quality of life (QOL), increased 
life expectancy or survival advantage, decreasing the insults to cardiovascular system 
thereby lowering risk of cardiovascular diseases (CVD), decreased mortality and lower 
economic burden/costs.
35–38
 
Many studies have reported a higher quality of life in patients that undergo renal 
transplantation to their counterparts that remained on the wait list with regular dialysis 
treatments.
32,35,36
 The major factors that contribute to the improved quality of life in renal 
transplant recipients include physical function/ability, greater independence, engagement 
in social and recreational activities, and increased ability to work.
25
 In addition to 
improved QOL, a 41% - 68% decrease in mortality has been reported in renal transplant 
recipients in comparison to those that tend to remain on the wait list. 
39,40
 
Over years, maintenance dialysis increases the risk of CVD associated mortality while the 
patients that are able to maintain the graft function following renal transplantation show 
continuous low CVD associated death rates, implying a long term reduction in the disease 
progression.
41
 In addition to the various medical benefits, there is a 3.5 fold more 
expensive to remain on dialysis versus a renal transplant. Surprisingly, renal 
transplantation and maintenance cost much less (~$250,000 less over a period of 5 years) 
than dialysis in the long term.
37,42
 
All the above-mentioned factors make renal transplantation a better option for patients 
affected with ESRD.   
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1.3 Ischemia/Reperfusion Injury 
Ischemia/reperfusion injury (IRI) is a pathological condition. As the name suggests, IRI is 
made up of two parts – ischemia and reperfusion. Ischemic injury happens when the 
blood supply to the organ is cut off leading to limited delivery of nutrients and oxygen.
43
 
Reperfusion follows ischemia with the subsequent restoration of the blood supply to the 
specific organ. Paradoxically, the restoration of blood supply to the organ enhances the 
cellular inflammatory responses that lead to IRI.
44
 It is known to be inevitable in the 
donated organs thereby impacting the functionality of the grafts after transplantation.  
1.3.1 IRI effects at cellular level 
There are multiple ways in which IRI can cause damage to a cell and these damages 
ultimately result in cell death through apoptosis, necrosis or autophagy.
43
 Apoptosis is 
caused by the action of intracellular signaling pathways that involve cellular caspases 
(caspase 3 and caspase 9). These caspases cleave the cytoskeletal proteins leading to the 
breakdown of the subcellular components.
45,46
 The main characteristics observed during 
apoptosis are the shrinkage of the nucleus and cell, chromatin condensation and nuclear 
fragmentation.
47
 Necrosis, on the other hand, is the cell death caused by swelling and 
eventual bursting. It happens due to the loss in integrity of cell membrane causing influx 
of the extracellular ions and fluid.
47
 Autophagy is different from apoptosis and necrosis. It 
occurs on a daily basis and is defined as a pre-programmed cell death by means of which 
the cells are able to recycle the unnecessary or damaged organelles and macromolecular 
components.
48,49
 However, under conditions of hypoxic stress and nutrient deprivation, 
our body uses this mechanism to provide the required substrates to the cells for 
metabolism.
47
  
During IRI, the hypoxic conditions limit the availability of oxygen molecules. The cells 
need oxygen as the final acceptor of electrons in the electron transport chain in 
mitochondria. Due to the lack of oxygen, the powerhouses of the cell (mitochondria) 
produce reduced amount of energy in the form of adenosine triphosphate (ATP) 
molecules and fulfill the needs of the cell.
50,51
 As a result, a number of ATP dependent 
ion channels in the cell membrane fail to function properly and it gradually leads to the 
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imbalance of cytoplasmic ions such as calcium (Ca
+2
), sodium (Na
+
) and hydrogen (H
+
).
50
 
This can lead to calcium overload that activates calcium dependent enzymes resulting in 
cell death or apoptosis. The hypoxic conditions also trigger the production of reactive 
oxygen species (ROS) in the mitochondria. These are free radicals and reactive molecules 
generated by molecular oxygen in the mitochondrial electron transport chain and include 
superoxides, hydroxyl anions and hydrogen peroxides. In addition, the hypoxic stress can 
cause the depolarization of mitochondrial membrane leading to a transition in the 
mitochondrial membrane permeability (MMPT).
50,52
 Due to the decreased membrane 
potential, high molecular weight molecules are now able to freely pass through the 
mitochondrial membrane into the cytoplasm through the special channels and cause 
cellular damage.
53
 
There are a number of proteins induced by I/R that play a major role in apoptosis and act 
in the mitochondria. The most well studied among these is the B-cell lymphoma (Bcl) 
protein family, which contains both pro-apoptotic (Bax, Bid) and anti-apoptotic members 
(Bcl-2, Mcl-1). It has been shown that the apoptotic process is initiated by caspase-8 that 
truncates the cytosolic protein Bid into tBid (Figure 1). The truncated tBid binds to the 
external mitochondrial membrane leading to the activation of Bax and Bak.
54
 Upon 
activation, these proteins tend to oligomerize in the mitochondrial outer membrane 
triggering the channels in the mitochondrial membrane that cause leakage of cytochrome 
c into the cytoplasm.
55
 When cytochrome c reaches the cytoplasm, it mediates formation 
of the apoptosome auto activating caspase 9. Active caspase 9 feeds the conversion of 
pro-caspase 3 into active caspase 3 which triggers eventual apoptosis.
56,57
  
Endogenously produced gaseous messenger molecules (gasotransmitters – discussed in 
the upcoming section) have been shown to be helpful in mitigating some effects of IRI 
however, their mechanism of action has not been elicited yet and is of great interest to the 
scientists.    
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Figure 1: Mitochondria associated apoptotic pathway. 
Representative image showing the role played by pro-apoptotic and anti-apoptotic 
molecules in apoptosis. The process can be initiated in the cells by hypoxia-induced stress 
that initiates the signaling pathway resulting in the activation of pro-caspase-3. The 
activated caspase-3 finally triggers apoptosis. (ROS – reactive oxygen species). 54-57 
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1.4 Gasotransmitter family  
Living beings contain a wide variety of signaling molecules ranging in size and chemical 
properties. They can be proteins, lipids, amines, or even gases. A gasotransmitter is 
defined as a gaseous messenger molecule that can activate a signaling process at the 
cellular level. For classification purposes, it must meet the conditions listed in Table 1 to 
qualify as a gasotransmitter.
58
 Currently, there are three known members of the 
gasotransmitter family – nitric oxide (NO), carbon monoxide (CO) and hydrogen sulfide 
(H2S).  
 
Table 1. Criteria for classification of a gasotransmitter 
(Modified table from Wang, R.; 2002) 
 
 
1 They are small molecules of gas, like nitric oxide (NO) carbon monoxide (CO) 
and hydrogen sulfide (H2S).  
2 They are freely permeable through the membrane and their effects do not depend 
on membrane receptors.  
3 They are endogenously and enzymatically generated in a regulated manner.  
4 They have well-defined specific functions at physiologically relevant 
concentrations  
5 Their cellular effects may or may not be mediated by second messengers, but 
should have specific cellular and molecular targets.  
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1.4.1 Nitric oxide and carbon monoxide 
The first gaseous molecule to be classified as a gasotransmitter was NO. It was 
discovered as an endothelium-derived relaxing factor and macrophage activator.
59
 It is 
produced endogenously during the conversion of L-arginine to L-citruline by the enzyme 
nitric oxide synthase (NOS) (Figure 2).
60
 There are three subtypes of the NOS enzyme – 
inducible NOS (iNOS), endothelium NOS (eNOS) and neuronal NOS (nNOS). While the 
iNOS is triggered during inflammatory conditions and immune responses, the eNOS and 
nNOS are constitutively expressed in the endothelial cell and neuronal/renal macula densa 
cells respectively. The physiological role of NO is to modulate platelet aggregation, assist 
in leukocyte adhesion and smooth muscle relaxation. However, under conditions of 
hypoxia and in the presence of ROS (such as superoxide ions), NO reacts to form 
peroxynitrite, which is a strong nitrating oxidant that causes depletion of antioxidants 
(such as glutathione) and contributes to the I/R damage.
58,60
 
CO was known to be formed physiologically long before the analysis of its physiological 
function.
61
 During the conversion of heme to biliverdin by the enzyme heme oxygenase 
(HO), CO is synthesized by the use of oxygen and energy molecule nicotinamide adenine 
dinucleotide phosphate (NADP) (Figure 2). Similar to NOS, there are three subtypes for 
HO – HO-1, HO-2 and HO-3. HO-1 is strongly induced under oxidative, chemical and 
physical stress in the cortical tubules and renal vasculature; HO-2 is constitutively 
expressed in the brain while HO-3 is another spliced version of HO-2.
60
 At physiological 
level and concentrations, CO plays anti-stress and anti-inflammatory roles by suppressing 
the production of inflammatory cytokines
62
, prevents arteriosclerotic lesions
63
 and 
provides cytoprotection by stabilizing hypoxia inducible factor.
64
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Figure 2: Endogenous production of NO and CO in cells. 
NO is produced from L-arginine yielding L-citrulline, a reaction catalyzed by three 
enzymes, nNOS, iNOS and eNOS. The half-life of NO is very short; it is metabolized 
within milliseconds. CO is produced from heme by HO-1, HO-2 and HO-3. [Modified 
figure from Snijder et al., 2013] 
 
 
 
L-arginine Heme
eNOS nNOS
Carbon monoxide
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HO-1 HO-3
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1.4.2 Hydrogen Sulfide 
Hydrogen sulfide has been recently added to the family of gasotransmitters.
58
 Historically 
known for its rotten egg smell and toxicity at higher concentrations, it was not until 1989 
that H2S production was detected endogenously.
65
 A few years later, it was proposed to 
be an endogenous neuromodulator due to its capability of enhancing N-methyl-D-
aspartate (NMDA) receptor mediated responses and induction of long term potentiation in 
hippocampus.
66
 Following these discoveries, it was also observed that H2S has the 
capacity to dilate blood vessels in various murine and in-vitro models.
67
 These 
characteristics intrigued research interests in the H2S molecule.  
Non-toxic levels of H2S are reported in micromolar quantities as it has been shown to 
exist at concentrations of 30μM – 300μM in the vertebrate blood.66,68 In the human body, 
at a temperature of 37ºC and pH of 7.4, 80% of H2S exists as a hydrogen sulfite ion    
(HS
-
).
69
 Most mammals produce endogenous H2S by using three enzymes - cystathionine 
gamma lyase (CSE), cystathionine beta synthase and 3-mercaptopyruvate 
sulfurtransferase (3MST) [Figure 3]. Cysteine is an essential precursor for all of these 
enzymatic pathways.
66,70
 In the kidneys, all three enzymes are primarily located in the 
proximal tubules in the renal cortex. While CBS and CSE are present in the cytosol of the 
cells, 3-MST is located in mitochondria as well as cytosol.
71
 In fact, these enzymes tend 
to relocalize to the mitochondria during stress conditions.  
Physiologically, the H2S plays an important role in preventing inflammation
72
, oxidative 
stress
73
, neuromodulation
66
, vasoregulation
74
 and inhibition of insulin resistance
75
. Further 
studies in animal models and human disease have shown that defective or less than 
optimal endogenous H2S production causes ageing
76
, cardiovascular diseases
77
 and 
respiratory pathologies like asthma
78
 and chronic obstructive pulmonary disease.
79
 In 
addition, involvement of H2S in cell functioning, cytoprotection and cellular signaling is 
being actively explored.  
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Figure 3: Enzymatic pathway for endogenous production of hydrogen sulfide. 
H2S is produced by CSE, CBS and 3MST from homocysteine, cystathionine, L-cysteine 
and D-cysteine. Cysteine aminotransferase (CAT) and D-amino acid oxidase (DAO) are 
required to convert L-cysteine and D-cysteine into 3-mercaptopyruvate (3MP) that is used 
as a substrate for H2S production by 3-MST.[Modified   from Snijder et al., 2013] 
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1.5 Hydrogen sulfide and IRI  
Numerous studies using in-vivo and ex-vivo models have demonstrated protective effects 
of H2S against IRI in various organ transplant models including that of the lung
80
, liver
81
, 
heart
82,83
 and kidney.
84,85
 The protection rendered by H2S in these studies is related to the 
physiological effects of H2S that are discussed in depth in the next section.  
1.5.1 Inflammation and H2S 
Inflammation is a protective physiological reaction of vascularized tissue to injury and 
can be categorized as acute or chronic, depending on the duration and mechanism of the 
reaction.
86
 Acute inflammation is the early host response that results in increased blood 
flow (vasodilation) and neutrophil infiltration to the site of injury, while chronic 
inflammation is of prolonged duration and may follow acute inflammation.
87
 
H2S plays opposing roles in inflammation. Some studies claim that H2S helps reduce the 
inflammatory processes while others show increased inflammation after use of H2S. 
However, the crucial fact that plays an important role in determining the impact of H2S on 
inflammatory processes is its concentration in that tissue or cell. Time and again, it has 
been shown that higher doses of H2S are toxic, pro-inflammatory and cause cell death
88
 
while lower physiological doses render protection from cell death.
72,74,82
  
Some studies have linked the decreased expression of pro-inflammatory molecules as one 
of the mechanistic pathways of protective H2S. An in-vivo study has shown a reduction in 
expression of tumor necrosis factor-alpha (TNF- α) following supplementation with 
H2S.
90
 TNF- α is a key member of the cytokine family. It plays a role in immune system 
during inflammation, cell proliferation, differentiation and apoptosis. 
91
 Many cell types 
produce this factor (T-cells, B-cells, neutrophils, etc.) following a stimulation by other 
cytokines or pathophysiological conditions.
92
 A study on human coronary endothelial 
cells has showed that TNF- α indirectly contributes to the ROS production in the sites of 
inflammation
93
 and caspase activation leading to apoptosis. 
94
 Thus, reduction in TNF- α 
can help mitigate some harmful effects of IRI.   
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1.5.2 Antioxidant effect 
ROS are produced in limited quantities under normal physiological conditions. As a 
result, the cells are easily able to detoxify the ROS by using specific enzymes such as 
glutathione peroxidase and superoxide dismutase; and other antioxidant molecules like 
glutathione and vitamins C & E.
95
 Glutathione is one of the most effective antioxidants 
present in our body. However, when ROS are produced in excess amount during IRI, they 
can damage the cell membrane and proteins; activate signaling pathways such as mitogen 
activated protein kinases (MAPK) and c-Jun-N-terminal kinase leading to apoptosis.
96
  
H2S has been shown to have direct and indirect antioxidant properties. It acts as a direct 
antioxidant by reducing reactive molecules and scavenging ROS radicals and anions.
97,98
 
Indirectly, H2S is known to up-regulate intracellular levels of glutathione and superoxide 
dismutase and thereby help in the removal of excessive ROS.
83
 In-vitro studies by 
Whiteman et al. on human neuro-epithelium cells have depicted reduced lipid 
peroxidation along with decreased cytotoxic effects of radical and non-radical 
intermediates (such as peroxynitrites and lipid hydro-peroxides) on protein nitration and 
oxidation upon treatment with H2S.
99,100
 Another study by Geng et al. also demonstrated 
protective effect of H2S on contractile activity of cardiac myocytes in rats by directly 
scavenging oxygen free radicals (superoxides and hydrogen peroxides) along with 
decreasing the accumulation of lipid peroxidations.
101
 
1.5.3 Protecting mitochondrial integrity and anti-apoptotic role 
During oxidative stress conditions, excessively produced ROS and calcium ions 
accumulate in the mitochondria as some of the ion channels fail to function properly in 
the absence of ATP.
50
 The hypoxic stress also causes depolarization of the mitochondrial 
membrane
52
 (discussed previously under “IRI effects at cellular level”). The MMPT 
eventually causes the breakdown of the mitochondria and the cell can no longer survive 
without the energy (ATP) to fuel its metabolism. In-vitro and in-vivo studies have shown 
that H2S treatment results in improvement of mitochondrial respiration recovery rate, 
increased efficacy of complex I&II and reduced mitochondrial swelling following IRI.
83
 
It also helps to scavenge the ROS present in the mitochondria by up regulating 
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glutathione and superoxide dismutase. Overall, H2S protects mitochondrial 
degradation/breakdown due to IRI.  
Studies have also reported the protective effects of H2S against apoptosis. In a murine 
model of oxidative stress related to hemorrhagic shock, Xu et al. demonstrated that H2S 
administration protected the lungs by suppressing oxidative stress and apoptotic signaling 
pathway along with decreasing the expression of various mitochondria associated and 
other apoptotic proteins such as active caspase 3/8, Bax and increased expression of anti-
apoptotic protein Bcl-2. Another study by Sivarajah et al. showed that H2S is associated 
with decreased apoptosis demonstrated by reduction in caspase 9 activity in the cardiac 
myocytes subjected to 25 minutes of ischemia and 2 hours of reperfusion in a rat 
model.
104
 Based on these studies, H2S seems to down regulate the proteins associated with 
apoptosis while up-regulating the ones that prevent cell damage and death.  
1.5.4 H2S donor molecules  
H2S exists as a gaseous form of matter. This physical property limits the use of this form 
since it would be hard to deliver and maintain accurate dissolved concentration of a gas. 
As a result, a variety of H2S donor molecules are being used to study the effects of H2S 
supplementation through in-vivo or in-vitro IRI models. 
Some of the natural compounds that are most commonly used to deliver H2S in research 
setting include salts like sodium hydrogen sulfide or sodium sulfide (NaHS/ Na2S), L-
cysteine and D-cysteine. While the crude sulfide salts provide exogenous H2S, the 
different isomers of cysteine help with the endogenous production of H2S. L-cysteine has 
been long known to contribute to endogenous production of H2S through the use of CBS, 
CSE and 3-MST enzymes. D-cysteine has only been recently identified as a novel 
pathway for endogenous H2S production via the use of DAO and 3-MST enzymes. 
However, the D-cysteine involving pathway is optimal at physiological pH 7.4 and 
independent of two pyridoxal 5’-phosphate (PLP) unlike the L-cysteine pathway that 
prefers alkaline pH and is PLP dependent. In addition, the D-cysteine has 80 fold greater 
H2S producing activity in the kidneys than the L-cysteine.
105
 Furthermore, the study by 
Shibuya et al. has demonstrated more efficient protection against IRI in the renal cortex 
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of mice following oral administration of D-cysteine in comparison to L-cysteine.
106
 This 
makes D-cysteine a better choice over L-cysteine for increasing the endogenous 
production of H2S.  
Although the sulfide salts (NaHS, Na2S) are readily available and convenient to use in 
laboratory, Whiteman et al. has listed a few drawbacks associated with the use of these 
molecules as H2S donors.
107
 First of all, salts like NaHS/ Na2S undergo instantaneous 
dissociation that generates H2S gas. The rapid dissolution causes a burst of the gas that 
could also lead to toxicity in the cell considering the basal plasma levels of H2S in 
vertebrates have been reported to be around 30μM to 300μM and the concentration of 
sodium sulfide salts used in research studies ranges from high micromolar to millimolar 
concentrations. In contrast, the endogenous enzymatic production of H2S is a slow and 
sustained process carried out by CBS, CSE and 3-MST.
60
 Further, the problem of zero 
sustainability of H2S release renders the cells susceptible to injury in the subsequent 
phases of IRI.  
These drawbacks prompted the search for slow releasing H2S donors that could continue 
releasing H2S over longer periods of time. This would also help to lessen the chances of 
toxicity since only limited amount of H2S is released in a given time. Moore and 
colleagues, at the National University of Singapore, developed the first water soluble 
slow-releasing H2S donor named as morpholin-4-ium 4 methoxyphenyl(morpholino) 
phosphinodithioate (GYY4137).
108
 The chemical synthesis equation is shown in figure 4 
and depicts the molecular structure of the molecule. In their study, it was observed that 
GYY4137 takes about 600 seconds to reach its peak rate of release and then maintains the 
release rate for over 180 minutes. This particular feature enables it to mimic the biological 
conditions where a sustained release of H2S is available to the cells when needed. Also, it 
should be noted that every molecule of GYY4137 releases two molecules of H2S and the 
decomposition products of this molecule seem to be inactive with no possible effects on 
the cells.
87
 Further, the final concentrations of H2S generated from GYY4137 are more 
physiologically, pathophysiologically and therapeutically relevant than those from the 
sulfide salts. Lastly, the water solubility of GYY4137 makes it very convenient for use in 
laboratory as it can be easily dissolved in water based solvents (cell culture medium as 
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well) without requiring specific organic solvents such as the dimethyl sulfoxide 
(DMSO).
109
 
A review of literature shows very similar protective effects of GYY4137 as the H2S 
molecule. As described previously, H2S plays a role in decreasing oxidative stress and 
preserving mitochondrial membrane potential during IRI. Likewise, GYY4137 has been 
shown to exert cytoprotective effects in cellular and animal models. For instance, 10μM - 
200μM dose range of this molecule impedes cytotoxicity induced by H2O2 and 
peroxynitrite in human mesenchymal progenitor cells and human articular chondrocytes. 
In the same study, it was shown to preserve mitochondrial membrane potential and 
inhibited ROS production in the mitochondria.
110
 Furthermore, a study on human 
umbilical vein endothelial cells (HUVEC) substantiated the role played by endogenous 
H2S in suppressing the cytotoxicity induced by H2O2 whereby the siRNA-mediated 
knockdown of CSE aggravated cellular injury.
111
 This supports the viable notion of 
therapeutic capability for H2S donor molecules. 
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Figure 4: Chemical equation for synthesis of GYY4137 
Morpholine [20mmol] (dissolved in methyl chloride) was added to of 2,4-bis(4-
methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane [4mmol] (dissolved in methyl 
chloride) in the presence of dichloromethane (DCM) at room temperature (RT). (Taken 
from Li et al., 2008)  
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1.6 Rationale, Hypotheses and Aims 
1.6.1 Rationale  
Our lab has previously shown that supplementation of organ preservation solution with 
H2S leads to significant survival and tissue protection at prolonged periods of cold 
ischemic stress (24 hours) followed by subsequent renal transplantation.
112
 We have also 
observed that H2S renders protection against warm renal IRI in a non-transplantation 
model of uni-nephrectomised rats involving 1 hour warm ischemia and 2 hours of 
reperfusion.
90
 Although numerous studies have shown the protective effects of H2S 
against renal IRI, not a lot has been explored in the field of DCD transplants that involve 
a combination of warm and cold ischemia. Through this study, I aimed to assess the 
protective effects of H2S supplementation in a murine model of DCD transplantation and 
further assess the mechanisms underlying the protective role of H2S in such a model. 
1.6.2 Hypotheses 
In-vivo 
Supplementing donor rats with a precursor H2S molecule and the cold organ preservation 
solution (UW) with exogenous H2S would accelerate renal recovery and improve graft 
function along with the recipient survival rates. 
In-vitro 
Addition of synthetic H2S donor molecule during hypoxia to the growth media of porcine 
kidney proximal tubular epithelial cells (LLC-PK1) would help attenuate 
pathophysiological effects of IRI at cellular level resulting in increased cell viability.   
1.6.3 Aims 
Aim 1: To compare renal function in the treatment and untreated group recipient rats by 
analyzing serum and urine samples 
Aim 2: To assess the renal graft obtained at end point or after death of the subject for 
apoptosis and glomerular/tubular necrosis using histological staining techniques (TUNEL 
stain & H/E stain) 
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Aim 3: To measure mRNA expression of various pro-inflammatory (TNF- α), pro-
apoptotic (Bax, Bid) and anti-apoptotic (Bcl-2] mediators 
Aim 4: To understand the underlying mechanism for protective effects of H2S using an 
in-vitro model  
 Aim 4.1: Develop a protocol for the in-vitro IRI model  
Aim 4.2: Study and quantify effect of GYY4137 on cells exposed to hypoxia and 
subsequent reoxygenation by measuring necrosis, late apoptosis and cell viability 
Aim 4.3: Assess the effect of H2S supplementation on mitochondrial apoptotic 
pathway by measuring changes in ROS, mitochondrial membrane potential and 
changes in expression of mitochondria associated apoptotic markers  
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Chapter 2  
2 Materials and Methods 
This section describes the different methods that were used to carry out the experiments 
covered under this project. It involved the use of both in-vivo and in-vitro methods.  
2.1 Murine Model of Donation after Cardiac Death (DCD) 
Renal Transplantation 
2.1.1 Animal description and care 
Adult male Lewis syngeneic rats (250g – 300g) purchased from Charles River 
Laboratories International Limited (USA) were used for this study to prevent any 
confounding effects of immunosuppression. The animals were maintained in accordance 
with the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory 
Animal Resources, National Research Council. The animals were housed at the animal 
facility located in the Animal Care and Veterinary Services Department at The University 
of Western Ontario. The experimental protocol and housing conditions followed the 
guidelines of the Council on Animal Care of the institution.   
2.1.2 Preliminary experiments and final experimental design 
The rats were randomly divided into one of the following three groups: sham, untreated or 
treatment. The sham group rats underwent a midline incision and the procedure did not 
involve kidney transplantation. On the other hand, the untreated and the treatment group 
rats received the donor kidneys that had experienced a combination of warm and cold 
ischemic injury.  
To decide the time intervals for warm and cold ischemia, some preliminary experiments 
were carried out. In the beginning, prolonged warm (45 minutes) and cold ischemic (18 
hours) times were used to maximize the amount of injury and to see a better difference 
between the untreated and treatment groups. However, the recipient rats were unable to 
survive past post-operative day two in both the groups. Thereafter, the warm ischemic 
injury time was lowered to 20 minutes while maintaining the same cold ischemic time so 
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as to make sure the grafts retained their function in the recipient. Due to the reduced 
injury to the donor kidney, the rats in both groups survived until the end point of 30 days. 
The serum creatinine levels showed slight differences between the untreated and the 
treatment group such that there was a faster recovery of renal function in the treatment 
group (Appendix A). However, the warm ischemia time did not appear to cause 
significant injury to the grafts as both the treatment and the untreated group recipients 
were able to recover from the induced injuries and survived until the end point.  
In the finalized experimental design (shown in Figure 5), the warm ischemic time was 
increased to 30 minutes and the cold ischemic time was 18 hours so as to cause sufficient 
damage to observe significant differences between the different experimental groups. The 
untreated and treatment group rats received the donor kidneys that had undergone 
clamping for 30 minutes and a cold storage period of 18 hours in the standard organ 
preservation solution called University of Wisconsin (UW) solution. The main differences 
between the untreated and the treatment group included injecting the donor rats with D-
cysteine prior to the surgical procedure and supplementing the organ storage and flush 
solution with hydrogen sulfide (H2S) as detailed in section 2.1.3.  
2.1.3 Surgical procedure 
The donor rats for the treatment group received an intraperitoneal (I.P.) injection of D-
cysteine (purchased from Sigma Aldrich Company, USA) dissolved in 0.5mL of sterile 
saline solution (0.9%NaCl) at a concentration of 2mmol/kg rat weight at least one hour 
prior to the clamping of the pedicle. The dosage and timing for D-cysteine injection was 
based on a study by Shibuya et al. where he orally administered D-cysteine at a dose of 
8mmol/kg of the body weight of mice and observed increased concentrations of H2S in 
those mice for up to 3 hours following ingestion.
106
 Taking into account the lower 
gastrointestinal absorption of the ingested drug, the donor rats were injected 
intraperitoneally with D-cysteine at 4mmol/kg body weight in our pilot experiment. 
However, none of the treatment rats survived in that experiment. Therefore, the dosage of 
D-cysteine was reduced to half that amount (2mmol/kg of rat weight) in our preliminary 
experiments and the treatment rats were able to survive following renal transplantation.  
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The rats were anesthetized by intramuscular injection of 0.2ml ketamine/xylazine and 
maintained under anesthesia with 2% isoflurane during surgery. In donor rats, the left 
renal pedicle was occluded via atraumatic clamping for 30 minutes to induce warm 
ischemia. The left kidney was then flushed with 5mL of UW solution and procured. 
Following procurement, it was stored in 50mL of the same solution at 4ºC for 18 hours to 
encounter cold ischemia. However, the UW flush and storage solution was supplemented 
with 150μM NaHS (sodium hydrogen sulfide) for the treatment group. The same dose 
(150μM NaHS) was also used in our other in-vivo IRI study in a rat model that involved 
extended periods of cold ischemic stress and showed beneficial effects. 
The recipient syngeneic Lewis rats underwent bilateral nephrectomy followed by renal 
transplantation of the left kidney procured from the donor. Each surgery was performed 
by the same experienced micro-surgeon (Dr. Jifu Jiang, Microsurgeon, Matthew Mailing 
Centre for Translational and Transplantation studies) who was blinded to the treatment 
group. The length of the surgery/operating time was similar for the untreated and the 
treatment group.   
2.1.4 Post-operative monitoring  
The recipient animals were monitored for a period of 30 days or until the time of death 
(whichever came first). Daily health records were maintained for these animals. No 
surgical complications were caused by the anastomoses that were carefully examined at 
the time of death or sacrifice. Blood and urine samples were obtained from these rats on 
post-operative days 3,5,10,20 and 30. The rats were placed in metabolic cages to collect 
urine while the blood samples (500μL) were taken from the tail vein. The blood was 
centrifuged at 12,000g for 5 minutes to separate the serum. The serum and urine samples 
were then stored at -20ºC for later analysis.  
2.1.5 Assessment of graft renal function and injury 
Serum obtained from the blood samples was analyzed at Core Pathology Laboratories 
(University Hospital, London Health Sciences Centre) for creatinine, urea and osmolality. 
The urine samples were also examined for creatinine and protein at the same lab facility. 
The creatinine and protein values from the urine samples were used to calculate the urine 
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protein-creatinine ratio (adjusted to the rat weight) as an indication of any prevalent signs 
of proteinuria in the recipients. The urine osmolality was measured in the lab using The 
Advanced
®
 Micro-Osmometer Model 3320 (Advanced Instruments Inc., Massachusetts, 
USA). Basically, 20μL of the sample was loaded into the sampler tip of the plunger and 
then inserted into the sample port. The test was run for approximately one minute and the 
readings were collected. In case of multiple samples being tested on the same day, sample 
port was cleaned properly before switching between samples. Also the first readings for 
the successive samples, following the first sample, were discarded and the second reading 
was recorded to prevent any errors due to sample contamination.  
2.1.6 Renal histopathology 
At the time of death or sacrifice, the kidney grafts were removed and bivalved sagitally 
such that one half was stored at -80ºC and used for qRT-PCR analysis while the other half 
was used for histological staining. The tissues were fixed in 10% formalin and sent to the 
Molecular Pathology Core Facility (Robarts Research Institute, London, Canada) for 
processing. The tissues were embedded, sectioned (8μm width) and stained with 
hematoxylin and eosin (H&E) to detect any signs of necrosis. All H&E sections were 
analyzed and quantified by an experienced clinical renal pathologist (Dr. Aaron Haig, 
London Health Sciences Centre) who was blinded to the treatment assignments. The 
slides were scored for acute tubular necrosis (ATN) on a scale of 0-5; where 0 represents 
absence, 1 denotes involvement of 1%-10% of glomeruli or cortical area, 2 is 11% - 25%, 
3 is 26% - 45%, 4 is 46% - 75% and 5 is greater than 75%.  
The histological sections also underwent terminal deoxynucleotidyl-transferase-mediated 
dUTP nick end labeling (TUNEL) to determine the level of apoptosis. All slides were 
analyzed by taking five pictures of random slide sections per sample using Nixon 
microscope at 10X magnification. The injury in the images was assessed using Image-J 
software by formulating a macro to precisely identify the dark stained cells in the slides. 
The total cell count for each picture was recorded and the median (from five pictures) was 
used to denote each sample.  
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2.1.7 RNA isolation, cDNA synthesis and real time PCR 
The rats that had either died or were sacrificed by post-operative day 3 for each of the 
sham, untreated and treatment groups were used to look at relative mRNA expression 
levels for certain inflammation and apoptosis related genes. A small part of renal tissue 
(containing both the cortex and medulla) measuring one gram in mass was cut from the 
sagitally bivalved kidney stored at -80ºC. It was thawed and immediately homogenized 
using a mechanical homogenizer and simultaneously adding cell disruption buffer 
(provided in the PARIS kit). The homogenate was placed on ice the whole time 
(including the time when it was being homogenized) to prevent any degradation of the 
mRNA or proteins. The total RNA content was isolated from the homogenate using 
Protein and RNA (PARIS) Isolation kit (life technologies, USA) as per the 
manufacturer’s protocol. Briefly, equal volumes (200μL) of cell lysis buffer (PARIS kit) 
and 100% ethanol were added to 200μL of tissue homogenate. The entire mixture 
(600μL) was centrifuged at 12000xg for 1-2 minutes in a collection tube with filter. The 
filtrate was discarded and the filter was washed sequentially with wash buffer 1 (one 
time) and wash buffer 2/3 (two times). The mRNA was recovered using the elution buffer 
(heated to 95ºC) with two sequential dilutions of 40μL and 10μL. All the buffers were 
provided with the PARIS kit. For reverse transcription, 4μL of SuperScript VILO™ 
MasterMix (Invitrogen) was added to about 400ng of mRNA and the sample volume was 
normalized to 20μL by addition of DEPC treated water (0.1% DEPC). The sample tubes 
were then placed in the Eppendorf thermal cycler set to the following cycles: 25ºC (10 
minutes), 42ºC (60 minutes) and 85ºC (5 minutes). After completion of the cycles, the 
cDNA samples were stored at 4ºC. The concentration and quality of the isolated mRNA 
and cDNA were analyzed using NanoDrop 2000. The A260/280 readings for the isolated 
mRNA and cDNA were consistently greater than 1.8 indicating little to no contamination.  
For qPCR, each sample used 2x SensiFAST SYBR Hi-ROX Mix (BIOLINE) and had a 
total volume of 20μL containing 20ng of respective cDNA. The forward and the reverse 
primer sequences were generated using the NCBI database and the IDT primer quest tool. 
The primers were ordered from Sigma Aldrich and the primer sequences are provided in 
table 3. The target gene signals were normalized against β-actin. All qRT-PCR assays 
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were performed using BIO-RAD thermal cycler and software package and the results were 
analyzed using Graph pad prism 6.   
2.1.8 Data analysis 
The data were analyzed using the Graph Pad prism 6 software. All statistical analyses 
involved use of either one-way or two-way ANOVA (with multiple comparisons) or 
Student’s t-tests (multiple) as required and the survival analysis was done using the 
Kaplan-Meier method. Statistical significance was accepted at p < 0.05 with a confidence 
interval of 95%. The values reported in results section (all figures) are mean ± standard 
error mean (SEM) unless otherwise stated.   
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Figure 5: Finalized experimental design for in-vivo murine model of DCD renal 
transplantation 
The figure shows three experimental groups – the treatment group (red), the untreated 
group (green) and the sham-operated (blue). The sham group rats only undergo a midline 
incision. In untreated and treatment groups, the donor rat’s kidney pedicle is clamped for 
30 minutes (warm ischemia) and then stored at 4ºC (cold storage/ischemia) for 18 hours. 
D-cysteine is injected intraperitoneally one hour prior to ischemic injury in donor rats and 
150 NaHS is added to UW solution only for the treatment group. The recipient rats 
undergo bilateral nephrectomy prior to the transplantation of the renal grafts and are 
monitored until the end point (30 days) or the time of death, whichever comes first. 
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Table 2. Primer sequences (rat) used in qRT-PCR reactions 
S. No. Gene  Sequence  5’  3’ 
1. B-actin forward GTGTGGATTGGTGGCTCTATC 
B-actin Reverse CAGTCCGCCTAGAAGCATTT 
2. BAX Forward TGCTACAGGGTTTCATCCAG 
BAX Reverse GACACTCGCTCAGCTTCTT 
3. BID Forward CGATACGGCAAGAATTGTGAAG 
BID Reverse ATTCCCACCACCTGGAAATAG 
4. Caspase-3 Forward CCACGGAATTTGAGTCCTTCT 
Caspase-3 Reverse CCACTCCCAGTCATTCCTTTAG  
5. BCL-2 Forward GTGGATGACTGAGTACCTGAAC  
BCL-2 Reverse GAGACAGCCAGGAGAAATCAA  
6. TNFα Forward GCAGATGGGCTGTACCTTATC 
TNF-α Reverse GAAATGGCAAATCGGCTGAC 
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2.2 DCD model in LLC-PK1 cells 
2.2.1 LLC-PK1 cell line 
The proximal tubular epithelial pig kidney cell line (LLC-PK1) was used for the in-vitro 
experiments. These cells were obtained in a frozen vial from the American Type Culture 
Collection (ATCC, Rockville, MD, USA). The cells were cultured in 75cm
2
 flasks in a 
carbon-dioxide incubator (5%CO2) at 37ºC using Medium199 (M199; Life Technologies 
Inc., USA) that contained penicillin (100 U/mL), streptomycin (100 U/mL) and was 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, 
USA). The cells were sub-cultured and plated onto twelve well plates upon reaching 80% 
- 90% confluence.  
2.2.2 Synthetic hydrogen sulfide donor used 
For the in-vitro experiments involving hypoxic injury, slow releasing synthetic hydrogen 
sulfide donor GYY4137 (courtesy of Dr. Matthew Whiteman from Exeter Medical 
School, England) was used to study the mechanism of hydrogen sulfide protection at a 
cellular level. Studies have shown that it reaches its peak rate of release approximately 
600s later than sodium hydrogen sulfide. Also, this molecule tends to maintain its peak 
release rate over a longer period of time rather than an initial burst observed in case of 
sodium hydrogen sulfide salts. 
2.2.3 Experimental design  
For all in-vitro experiments, 2x10
5
 cells suspended in 1mL of Medium199 (10%FBS, 1% 
Penicillin/Streptomycin) were plated in each well in the 12-well plate and allowed to 
grow in the carbon-dioxide incubator for 36 hours. During the experimental conditions, 
Dulbecco’s Modified Eagle’s Medium (DMEM; without any glucose or FBS) was used to 
restrict the supply of nutrients to the cells. Upon reaching 80% - 90% confluence, 
hydrogen sulfide donor molecule (GYY4137) dissolved in DMEM at varying 
concentrations (500nM – 500μM) was added to the wells. The plates were then placed in 
the hypoxia chamber (H85 Whitley hypoxy-station) set to 1% oxygen, 5% carbon dioxide 
and 94% nitrogen thereby limiting oxygen supply to mimic the conditions experienced 
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during ischemic injury. For warm conditions, the temperature of the hypoxia chamber 
was set to 37ºC while for the cold conditions the lowest internal temperature achieved in 
the chamber was 7ºC – 8ºC and the 12 well plates had to be placed on ice packs to reach 
temperature of 4ºC. A thermometer was placed beside the plates on the ice pack to verify 
the temperature experienced by the cells. 
In the beginning, a number of trials were conducted to finalise a combination of warm 
and cold hypoxic interval that would cause enough damage to the cells thereby lowering 
their viability by at least 40% - 50%, but at the same time the damage caused had to be 
reversible such that the cells could be rescued from that damage with the treatments being 
provided. These combination times included 3 hours warm + 3 hours cold, 3 hours warm 
+ 9 hours cold, 4 hours warm + 6 hours cold and 4 hours warm + 8 hours cold (Figure 
12). In all these combination experiments, it was observed that the ischemic injury (as 
measured by the percentage of viable cells) did not change by a large extent with the 
increases in the cold hypoxic time but depicted some change when the warm hypoxic 
time was increased. In order to see a significant difference in rescue, the hypoxic time 
was further increased and the percentages of viable cells were compared between the 
following hypoxic treatments: 12 hours warm + 24 hours cold and 12 hours warm (only).  
Based on the results (as described in the result section), the future experiments were 
conducted with the 12 hours of warm hypoxic time. 
2.2.4 Viability analysis 
After experiencing 12 hours of warm hypoxic time, the 12 well plates were taken out of 
the hypoxia chamber. The DMEM (media) from the wells was centrifuged at 500 x g for 
5 minutes to collect any floaters or dead cells in it. These dead cells were suspended in 
1mL of Medium199 (1% penicillin/streptomycin and 10% FBS) and re-added to the same 
wells. The plates were placed in the carbon-dioxide incubator (at 37ºC, 5%CO2) for 24 
hours allowing reoxygenation and associated injury.  
Following reoxygenation, the cell samples were analyzed for the percentage of viable 
cells. Briefly, the reoxygenation media was collected in labeled flow tubes. The wells 
were washed with 1X phosphate buffered saline (PBS) solution to remove any traces of 
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FBS in the wells and 100μL of 0.25% trypsin (Gibco, Life technologies, USA) was added 
to each well to lift the monolayer of cells. The plates containing trypsin were incubated at 
37ºC for 3-6 minutes to accelerate the process. Following incubation, 500μL of 
medium199 (1%Penicillin/Streptomycin, 10%FBS) was added to the wells to inactivate 
the trypsin and the medium (now containing the trypsinized cells) was collected in the 
same flow tubes. Two samples of heat-killed cells (65ºC, 10 minutes) were used as 
positive control for the stains. The flow tubes were then centrifuged at 600 x g for 6 
minutes to get a rigid pellet of cells at the bottom. The supernatant was removed and the 
cells were washed with 1X-PBS two times by re-suspension and centrifugation. The final 
pellet of cells was suspended in 100μL of Annexin-V binding buffer (Biology Legend, 
USA). Following suspension, 1μL of PE conjugated Annexin-V (Biology Legend, USA) 
and 3μL of 7- Aminoactinomycin-D (7-AAD; Bio Legend, USA) stains were added to 
each tube and allowed to incubate in dark for 15 minutes. The stained samples were then 
analyzed using the Beckman Coulter FC 500 flow cytometer (Beckman Coulter Canada, 
ON).  Two channels, FL2 with 572BP filter for PE conjugated Annexin-V and FL4 with 
675 BP filter for detecting 7-AAD, were used to assess the viability of cell samples.  
2.2.5 Quantification of reactive oxygen species 
The amount of reactive oxygen species was also quantified in the treatments. Briefly, the 
treatment group (DMEM only, DMEM with 50μM GYY4137) plate was taken out from 
the hypoxia chamber. The DMEM (cell media) was collected in labeled flow tubes and 
the wells were re-perfused in medium199 (no phenol red, 10%FBS, 1% P/S) for half an 
hour in the incubator. Following the re-perfusion, the cells were trypsinized and cell pellet 
collected using the same procedure and steps used for viability analysis. For the positive 
control, the cells were suspended in 500μL of 1XPBS containing 3% hydrogen peroxide 
(H2O2) for about 10 minutes prior to the collection of cell pellet. The cell pellets were 
then suspended in 100μL of 1X-PBS and 2μL of 1mM stock dihydrorhodamine 123 
(DHR 123, Life technologies, USA) stain was added to each flow tube. The tubes were 
incubated in the dark for about 15 minutes before being analyzed in the flow cytometer 
(Beckman Coulter) using FL1 channel.   
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2.2.6 Detection of mitochondrial membrane depolarization 
The cell samples were also analyzed for changes in the mitochondrial membrane 
permeability by using the stain JC-1 (Invitrogen, Life Technologies) for flow cytometry. 
Following the hypoxic injury (12 hours warm in hypoxia chamber), the media from the 
wells was collected in the centrifuge tubes and the wells were washed with 1X PBS to 
remove any traces of media. The cells were then trypsinized (with 0.25% trypsin and 3-5 
minutes incubation) and 500μL of medium199 (1%Penicillin/Streptomycin, 10%FBS) 
was added to the wells to inactivate the trypsin. The medium containing the trypsinized 
cells was collected in the same flow tubes. A sample of heat-killed cells (65ºC, 10 
minutes) was used as a positive control for the stain. The flow tubes were centrifuged at 
600 x g for 6 minutes to get a rigid pellet of cells at the bottom. The supernatant was 
removed and the cells were washed with 1X-PBS two times by re-suspension and 
centrifugation. The final pellet of cells was suspended in 100μL of medium199 and 1μL 
of JC-1 stain was added to the tubes. The tubes were then placed in the carbon dioxide 
incubator at 37ºC for 15 minutes and analyzed using the FL1 channel on flow cytometer.   
2.2.7 Measuring mRNA expression of apoptosis related proteins 
The total RNA content was isolated from the cells following 15 minutes of reoxygenation 
with M199 media after 12 hours of warm hypoxia. The wells were washed with 1X PBS 
twice to remove any traces of media. About 1mL of Ribozol® was added to the each well 
and allowed to sit for 4-5 minutes. The cell homogenate was passed through the pipette 
tip 3 times before collecting it in an eppendorf tube. The mRNA was extracted from the 
homogenate using the Pure Link® RNA Mini Kit (ambion® by Life Technologies, USA). 
Briefly 700μL of 70% ethanol was added to each tube and centrifuged in the spin 
cartridge at 12000xg for 15 seconds. The filtrate was discarded and the filter was washed 
sequentially with wash buffer 1 (one time) and wash buffer 2/3 (two times). The mRNA 
was finally recovered using the 30μL of RNAase-free water. All the buffers were 
provided with the kit. For reverse transcription, 4μL of SuperScript VILO™ MasterMix 
(Invitrogen) was added to about 300ng of mRNA and the sample volume was normalized 
to 20μL by addition of DEPC (0.1%) treated water. The sample tubes were then placed in 
the Eppendorf thermal cycler set to the following cycles: 25ºC (10 minutes), 42ºC (60 
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minutes) and 85ºC (5 minutes). After completion of the cycles, the cDNA samples were 
stored at 4ºC. The concentrations of the isolated mRNA and cDNA were measured using 
nanodrop. The A260/280 readings for the isolated mRNA and cDNA were consistently 
greater than 1.8 indicating little to no contamination.  
For qPCR, each sample used 2x SensiFAST SYBR Hi-ROX Mix (BIOLINE) and had a 
total volume of 20μL containing 20ng of respective cDNA. The forward and the reverse 
primer sequences were generated using the NCBI database and the IDT primer quest tool. 
The primers were ordered from Sigma Aldrich and the primer sequences are provided in 
table 4. The target gene signals were normalized against β-actin. All qRT-PCR assays 
were performed using BIO-RAD thermal cycler and software package and the results were 
analyzed using Graph pad prism 6. 
2.2.8 Data analysis 
The data were analyzed using the Graph Pad prism 6 software. All statistical analyses 
involve use of either one-way or two-way ANOVA (with multiple comparisons) or 
Student’s t-test as required. Statistical significance was accepted at p < 0.05 or lower with 
a confidence interval of at least 95% or higher depending on the p-value. The values 
reported in results section (all figures) are mean ± standard error mean (SEM) unless 
otherwise stated. 
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Table 3. Primer sequences for qRT-PCR in LLC-PK1 cell samples 
S. No. Gene Sequence 5’  3’ 
1. B-actin forward TCTGGCACCACACCTTCTA 
B-actin Reverse TCTTCTCACGGTTGGCTTTG 
2. BAX Forward CCCTTTTGCTTCAGGGGATGA 
BAX Reverse CCGCCACTCGGAAAAAGACT 
3. BID Forward GGATTCTAAGGTCAGCAACGGT 
BID Reverse GGATTCTAAGGTCAGCAACGGT 
5. BCL-2 Forward AGGATAACGGAGGCTGGGATG  
BCL-2 reverse AGGATAACGGAGGCTGGGATG 
6. MCL-1 Forward CTAGAAGGCGGCATCAGAAA 
MCL-1 Reverse GTGGCTGGAGTTGGTTAAGA 
7. EDN-1 Forward CTGCACTCCGCCTAAAGTATT  
EDN-1 Reverse GATTTCCACGAGGCTAGGATTT 
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Chapter 3  
3 Results 
The objective of our study was to evaluate the role of H2S supplementation in attenuating 
the effects of IRI in an in-vivo murine model of donation after cardiac death and study the 
underlying mechanisms in an in-vitro model of IRI using porcine proximal tubular 
epithelial kidney cells. The results from the current study are explained in the next 
sections.  
3.1 Murine Model of Donation after Cardiac Death 
The sham-operated rats underwent a midline incision only while the untreated and the 
treatment group rats received the donor kidneys that had experienced 30 minutes of warm 
ischemia (clamping) and 18 hours of cold storage in either UW solution alone or UW 
supplemented with 150μM NaHS respectively. The treatment group donor rats had also 
received 2mmol/kg D-cysteine I.P. one hour prior to the clamping of the pedicle. This in-
vivo murine model assesses the effect of H2S supplementation on recipient survival, graft 
function and renal injury by analyzing blood serum, urine and renal graft tissue samples 
and the results are described below.   
3.1.1 Increased survival in treatment group rats 
Following renal transplantation, the rats were observed for 30 days. Each group 
(untreated – cold storage in UW only; treatment – donors received 2mmol/kg D-cysteine 
I.P. and cold storage in UW +150μM NaHS; and sham – no renal transplant) contained 
six rats and the sham rats depicted a 100% survival showing efficiency of the surgical 
technique. Three out of six untreated group rats died on post-operative day 1,2 and 9 
respectively. The other three rats from the untreated group survived till the end point (day 
30). However, only one treatment rat died on post-operative day 2 while the rest were 
sacrificed upon reaching the end point. Overall, the treatment group rats showed an 
increased survival percentage in comparison to the control rats (Figure 6). A significant 
difference was observed between the survival curves of the three groups (p< 0.05) 
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indicating a trend between the groups as per the log rank test for trend used for survival 
curve analysis. 
3.1.2 Serum analysis indicates a trend of improved graft function in 
treatment group 
The serum samples collected from the blood of renal transplant recipients (untreated & 
treatment group) and sham-operated rats were analyzed for various parameters such as 
serum creatinine, urea and osmolality to compare the renal graft function among the 
different experimental groups.  
The serum creatinine values indicate a trend depicting much faster and consistent 
recovery in the treatment group (Figure 7). The creatinine values decrease rapidly and 
approach the sham baseline levels by post-operative day 10 in the treatment group rats. 
However, for the untreated rats, the creatinine levels show a comparably slow recovery 
during the initial period following transplantation. One should also keep in mind that half 
of the untreated group rats that were not doing well were dead by postoperative day 9. As 
a result, the serum creatinine values for the untreated group rats that did survive the initial 
vulnerable period were very close to the sham levels.  
The serum urea and osmolality levels were also measured and are shown in figures 8 (A) 
& 8(B), respectively.  The serum urea levels followed the same pattern like the serum 
creatinine (as expected) since both of them mark the ability of the kidneys to remove 
waste products from the body. The osmolality levels remained consistent among the rats 
throughout the experimental period indicating normal physiological functioning in these 
animals.  
Although there is a trend showing reduction in delayed graft function among the 
treatment group rats, no statistically significant differences were observed between the 
untreated and the treatment group rats in terms of the creatinine, urea and osmolality 
measured in blood serum on any post – operative day. 
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3.1.3 Urine analysis demonstrates reduced injury in treatment group 
The urine collected from the rats on day 3, 5, 10, 20 and 30 was analyzed by measuring 
the amount of protein and creatinine in the urine. These values were then used to calculate 
the protein to creatinine ratio, which is an indicator of injury to the renal graft. It was 
observed that the transplant recipient rats had higher ratio in comparison to the sham-
operated rats as expected (Figure 9). Upon statistical analysis using two-way ANOVA 
with multiple comparisons, statistically significant difference was observed between the 
untreated and the treatment group rats on post-operative day 5 (p<0.05) with a higher 
protein to creatinine ratio in the untreated rats in comparison to the treatment group.  
The urine osmolality was also measured in these samples and is shown in figure 10. The 
urine osmolality in the transplant recipients (both untreated and treatment groups) was 
observed to be significantly lower (** = p<0.01, *** = p<0.001, **** = p<0.0001) than 
the sham group rats using two-way ANOVA with Tukey’s multiple comparisons test. 
Over the time period of 30 days, the osmolality values did seem to increase at a steady 
rate for both the untreated and the treatment group rats. However, the values did not reach 
the baseline levels within this time period.  
3.1.4 ATN scores depict higher histological injury in untreated rats 
The scores from the H&E slides scored by the pathologist blinded to the treatment groups 
are shown in figure 11. The sham group rats did not show any histological injury as 
indicated by the consistent score of ‘0’ across all five rats. The untreated group rats 
showed a wider range of injury scores. However, the untreated group rats that were 
sacrificed on post-operative day 3 showed significantly higher injury score than the sham-
operated rats (* = p<0.05 using two-way ANOVA with Tukey’s multiple comparisons 
test). In addition, the treatment group rats scored lower on the injury scale and no 
statistically significant difference was observed between the sham operated and treatment 
group rats.  
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3.1.5 Comparable amount of apoptosis observed in the untreated and 
treatment group renal transplant recipients  
Using the TUNEL stain, the tissue samples collected from different experimental groups 
on post-operative day 30 were evaluated for the amount of apoptosis in them. The images 
of the TUNEL stain slides upon analysis with image-J software did not show any 
statistically significant differences between the untreated and the treatment group rats 
(Figure 12).   
3.1.6 Trends in mRNA expression of pro-apoptotic, anti-apoptotic and 
inflammatory markers in the collected tissue  
The results from qRT-PCR depicted some trends in the expression levels of various 
apoptosis related genes (Figure 13). Although no statistically significant differences were 
observed, mRNA analysis indicated a trend towards reduced expression of pro-apoptotic 
genes (such as caspase-3, Bax and Bid) and pro-inflammatory gene (TNF-α) in the 
treatment group tissue samples (n=4) and increase in the anti-apoptotic marker Bcl-2 in 
both the untreated and treatment groups.  
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Figure 6: D-Cysteine and H2S supplementation improved survival of renal 
transplant recipients. 
The graph shows the survival rates of sham-operated rats and renal graft recipients from 
the treatment and untreated group rats. The donor rats for the treatment group were 
injected I.P. with D-cysteine (2mmol/kg) and the donor kidneys were perfused and stored 
in UW solution supplemented with 150μM NaHS. The donor kidneys for the untreated 
group were perfused and stored in UW solution alone (n = 6 in each group; * = p < 0.05 
as per the log rank test for trend among survival curves). 
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Figure 7: D-Cysteine and H2S supplementation indicates a trend of accelerated 
recovery in renal graft function following ischemic injury to the renal grafts 
The graph shows the levels of serum creatinine in the sham-operated rats and renal graft 
recipients from the untreated and treatment groups on post-operative day 3, 10, 20 and 30. 
The donor rats for the treatment group were injected I.P. with D-cysteine (2mmol/kg) and 
the donor kidneys were perfused and stored in UW solution supplemented with 150μM 
NaHS. The donor kidneys for the untreated group were perfused and stored in UW 
solution alone (Values are Mean ± SEM, n = 6 in each group but varies for different days 
because of variation in survival; differences statistically not significant). 
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Figure 8: (A) Serum urea levels depict similar trends as serum creatinine and (B) 
serum osmolality remains consistent across different experimental groups over the 
time course of experiment  
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The graphs show the levels of serum urea and osmolality in the sham-operated rats and 
renal graft recipients from the untreated and treatment group on post-operative day 3, 10, 
20 and 30. The donor rats for the treatment group were injected I.P. with D-cysteine 
(2mmol/kg) and the donor kidneys were perfused and stored in UW solution 
supplemented with 150μM NaHS. The donor kidneys for the untreated group were 
perfused and stored in UW solution alone. (Values are Mean ± SEM, n = 6 total in each 
group but varies for each day depending on survival as per the experimental group; 
differences between untreated and treatment groups not significant statistically)  
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Figure 9: Urine protein to creatinine ratio indicating inferior kidney function in the 
untreated group rats in comparison to the treatment group rats 
The graph depicts urine protein to urine creatinine ratio in the sham-operated rats and 
renal graft recipient rats from the untreated and treatment group on post-operative days 3, 
5, 10, 20 and 30. H2S supplementation in the treatment rats provided some protection 
against ischemia reperfusion injury lowering the ratio. A significant difference (p<0.05) 
in the ratio was observed between the untreated and the treatment group on post-operative 
day 5. (n=3 in untreated and treatment group; n=5 in sham operated group; * = p < 0.05 
using two-way ANOVA with Tukey’s multiple comparisons test) 
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Figure 10: Decreased urine osmolality in the renal transplant recipients in 
comparison to the sham-operated rats 
The graphs show urine osmolality in the sham-operated rats and renal graft recipient rats 
from the untreated and treatment group on post-operative day 3, 5,10, 20 and 30. The 
donor rats for the treatment group were injected I.P. with D-cysteine (2mmol/kg) and the 
donor kidneys were perfused and stored in UW solution supplemented with 150μM 
NaHS. The donor kidneys for the untreated group were perfused and stored in UW 
solution alone. The urine osmolality is significantly lower in the renal transplant 
recipients in comparison to the sham-operated rats. (Values are Mean ± SEM, n=3 in 
untreated and treatment groups; n=5 in sham operated group,** = p<0.01, *** = p<0.001, 
**** = p<0.0001 using two-way ANOVA with Tukey’s multiple comparisons test) 
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Figure 11: H2S supplementation reduces tissue injury following ischemia 
reperfusion injury 
The H&E tissue slides scored by the pathologist blinded to the treatment groups showed 
significant (p<0.05) difference in the acute tubular necrosis scores for the untreated group 
and the sham operated rats that were sacrificed on post-operative day 3 depicting higher 
injury in the untreated rats. No significant differences observed between the experimental 
groups from the tissues collected on post-operative day 30 (* = p<0.05 using two-way 
ANOVA with Tukey’s test for multiple comparisons).   
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(A)                        (B)  
(C)  
Figure 12: Number of apoptotic cells in kidney tissue collected from untreated group 
and treatment group of rats on post operative day 30. 
Image of TUNEL stained tissue sections from untreated group (A) and treatment group 
(B) at 10X magnification. The scatter plot (C) shows the number of median apoptotic 
cells in the graft samples from the two groups counted using the Image-J software. The 
subjects shown above had survived until the end point of post-operative day 30. 
(Differences between the untreated and treatment group were not statistically significant) 
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Figure 13: Differences in the mRNA expression of various apoptosis related genes. 
A trend indicating some down-regulation in the expression of pro-apoptotic and 
inflammatory markers (Caspase-3, Bid and TNF-α) was observed in the treatment group 
while the Bax expression remained at the basal level (as in sham group). The untreated 
group depicted a trend towards increased expression of Caspase-3 and Bax that feed the 
apoptosis-signaling cascade. However, no statistically significant differences were 
observed. (Values are Mean ± SEM, n=4 in untreated and treatment group; n=2 in sham-
operated group)  
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3.2 In-vitro DCD Model 
For the in-vitro aspect of this project, the porcine proximal tubular epithelial kidney cells 
were exposed to hypoxic injury in a serum and glucose deprived media and any changes 
in cell viability (following 24 hour reoxygenation), quantities of ROS and mitochondrial 
membrane potential were measured using the stains Annexin-V/ 7-AAD, DHR 123 and 
JC-1 with flow cytometry respectively. These changes were then compared to the cell 
samples treated with H2S donor GYY4137 (50μM). We also looked at the m-RNA 
expression of apoptosis and injury related marker proteins in our treated and untreated 
cell samples using qRT-PCR.  
 Preliminary experiments helped us to choose the time interval for inducing adequate 
hypoxic injury to LLC-PK1 cells. As shown in figure 14, the increases in cold hypoxic 
time from 4hours warm + 6hours cold to 4hours warm + 8hours cold does not impact the 
cell viability and the mean viability of hypoxic samples stays around 65%. In addition, 
the amount of cell death in 12hours warm + 24 hours cold hypoxic time is comparable to 
the 12 hours warm alone hypoxia as in both these cases the cell viability goes down by 
35%.  
3.2.1 GYY4137 improved cell viability and decreased necrosis and 
late apoptosis in LLC-PK1 cells experiencing IRI 
The dose response curve for GYY4137 showed the protective effects of H2S 
supplementation on cell viability. The flow analysis scatter plots and bar graph (Figures 
15 and16, respectively) show that the cell viability increases by almost 25% with 50μM 
and 500μM doses of GYY4137. The percentage of viable cells in untreated (DMEM) 
samples was 51% while it increased to ~ 74% in cell samples treated with H2S donor 
(DMEM + 50μM/500μM GYY4137). There was a statistically significant difference 
(p<0.05, two way ANOVA with Tukeys test for multiple comparisons) observed between 
the percentages of viable cells in the untreated (DMEM with no GYY4137) and treated 
(DMEM + 50 μM GYY4137) cell samples.  
Some difference was also observed in the amount of necrotic and late-apoptotic cells 
while little to no early apoptosis was detected (Figure 17). The percentage of necrotic 
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cells decreased from 39% in untreated cells to approximately 20% in the cells treated with 
50μM and 500μM of GYY4137. A similar decline was observed in the percentage of late 
apoptotic cells from 9% in untreated samples to 4.5% with the same concentrations of 
GYY4137. However, the differences between percentages of necrotic and late-apoptotic 
cells in the treated and untreated samples were not found to be statistically significant and 
the experiment would need to be repeated in order to discover statistically significant 
differences.      
3.2.2 GYY4137 supplementation indicated a trend in reduction of 
cells with detectable ROS  
A trend indicating reduction in the percentage of cells with reactive oxygen molecules is 
evident in figure 18. Although the differences are not statistically significant and further 
experiments would be needed to increase the number of samples for finding statistically 
significant differences, but the current trend in results looks promising as the exogenous 
supplementation with H2S donor helped decrease the amount of cells with detectable 
ROS. Under normoxic conditions, the percentage of healthy cells (Media) with ROS is 
around 8%. When these cells are deprived of FBS and glucose, the percentage of cells 
with ROS goes up to 22% at normal oxygen concentrations. The same glucose/FBS 
deficient conditions under hypoxia increase the percentage of cells with ROS to 40%. 
However, addition of 50μM GYY4137 reduces the ROS and thereby lowers the 
percentage of cells with detectable ROS to 33%.  
3.2.3 Trend depicting decline in depolarization of the mitochondrial 
membrane in cells treated with GYY4137  
Supplementation with exogenous H2S donor also helped decrease the percentage of cells 
with depolarized mitochondrial membrane as shown by the trend observed in figure 19. 
The untreated cell samples showed approximately 13% of cells with depolarized 
mitochondria. Upon treatment with 50μM GYY4137, the percentage of cells with 
depolarized mitochondrial membrane decreased to about 10% indicating a role played by 
H2S in mitochondrial membrane permeability transition. However, no significant 
differences were observed between the treated and the untreated cell samples and a higher 
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number of sample numbers from future experiments would be needed to elucidate 
statistically significant differences between the two groups. 
3.2.4 Up-regulation of anti-apoptotic proteins and down-regulation of 
injury related proteins in treated cells following hypoxia 
Analysis of mRNA samples showed significant differences in the expression of various 
apoptosis and injury related markers in the cell samples (Figure 20). A significant 
increase in the expression of anti-apoptotic markers Mcl-1(p<0.001) and Bcl-2 (p<0.01)  
was observed in cells treated with 50μM GYY4137 in comparison to untreated hypoxic 
cells. There was also a significant reduction in the expression of injury marker EDN-1 in 
the treated samples (p<0.01) in comparison to the untreated hypoxia exposed cell 
samples. However, a trend of decreased expression of pro-apoptotic molecules (not 
statistically significant) was observed across all samples (whether treated or untreated) 
consistently.  
. 
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Time (hours) 
Figure 14: Different combinations of warm and cold hypoxic times and resulting 
impact on cell viability. 
Preliminary experiments indicating little to no change in hypoxic sample’s cell viability 
upon incremental increases in just the cold hypoxic time. Statistically significant negative 
impact observed on cell viability in 4hours warm + 8 hours cold (p<0.05), 12hours warm 
+ 24 hours cold (p<0.01) and 12 hours warm alone (p<0.001) conditions in comparison to 
normoxic-healthy cells. (W = warm hypoxic hours, C = cold hypoxic hours; Values are 
Mean ± SEM, n=4 in each group, * = p<0.05, ** = p<0.01, *** = p<0.001 using 
Student’s t-test) 
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(A)     (B)  
 
(C)    (D)  
Figure 15: Flow analysis scatter plots obtained from Annexin-V and 7-AAD staining 
The plots above represent the healthy cells under normoxic conditions in incubator (A), 
the hypoxic untreated samples (B) and cell samples supplemented with 50μM and 500μM 
GYY4137 respectively(C & D). The x-axis is representative of Annexin-V stain and y-
axis represents 7-AAD stain. The upper left quadrant marks the necrotic cells, lower left 
quadrant has the healthy cells, the upper right quadrant shows the late apoptotic/ 
necroptotic cells while the lower right quadrant has the early apoptotic cells.  
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Figure 16: Increased percentage of viable cells upon supplementation with 
GYY4137. 
Cell samples exposed to 12 hours hypoxia and 24 hours reoxygenation (at 37ºC) were 
analyzed for cell viability using Annexin-V and 7-AAD stains with flow cytometer. 
Adequate concentration of GYY4137 (50μM) helps mitigate effects of hypoxia-
reoxygenation injury in LLC-PK1 cells. The cell viability is significantly improved in the 
treatment group (p<0.05) in comparison to the untreated group. (Values are Mean ± SEM, 
n=3 in each group, * = p<0.05 using two-way ANOVA with Tukey’s test for multiple 
comparisons) 
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Figure 17: Trend depicting decrease in percentages of necrotic and late apoptotic 
cells after supplementation with H2S donor. 
The percentage of necrotic and late apoptotic cells is reduced to half the amount of that 
observed in untreated samples after experiencing 12 hours of hypoxia at 37ºC followed by 
24 hours of reoxygenation. The cells were analyzed using the Annexin-V and 7-AAD 
stains using flow cytometer. (Red = percentage of necrotic cells, Blue = percentage of late 
apoptotic/necroptotic cells; Values are Mean ± SEM, n=3 in each group, differences are 
not statistically significant) 
 
 
 
 
D
M
E
M
 
50
0n
M
5µ
M
50
µM
50
0µ
M
0
20
40
60
P
e
rc
e
n
ta
g
e
 o
f 
c
e
ll
s
 (
%
)
Necrosis
Necroptosis/Late Apoptosis
57 
 
(A)   (B)  (C)  
(D)  
Figure 18: Trend indicating reduction in percentage of cells with reactive oxygen 
species upon H2S supplementation. 
Following 12 hours of hypoxia, treated and untreated cell samples were stained with 
DHR123 and analyzed with flow cytometer. The histographs from flow analysis show the 
unstained-negative untreated (A), positive control - cells treated with 3% H2O2 in PBS for 
10 minutes (B), and a sample of untreated cells after hypoxia (C). The bar graph in (D) 
shows reduced percentage of cells with ROS upon supplementation with 50μM of 
GYY4137 during hypoxic phase. (Mean ± SEM, n=4 in each group, differences 
statistically not significant) 
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(A)     (B)    (C)  
(D)  
Figure 19: Trend depicting decreased percentage of cells with depolarized 
mitochondrial membrane in treated sample. 
The scatter plots from flow analysis show healthy cells (A), heat killed positive control 
(B) and untreated (DMEM only) cell sample (C) stained with JC-1 molecule following 12 
hours of hypoxia at 37ºC. The bar graph (D) shows a trend of decrease in percentage of 
cells with depolarized mitochondrial membrane upon addition of 50μM GYY4137 during 
hypoxic conditions. (Values are Mean ± SEM, n=4 in each group, differences statistically 
not significant) 
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Figure 20: Up-regulation of anti-apoptotic proteins while down regulation of injury 
markers observed with H2S supplementation. 
Increase in mRNA expression of Bcl-2 and Mcl-1 (anti-apoptotic proteins) along with 
decreased expression of injury marker EDN-1 observed in cells treated with 50μM 
GYY4137. The pro-apoptotic markers were down regulated in all samples irrespective of 
H2S supplementation. (Values are mean ± SEM and n=4 in each group; two-way 
ANOVA with Tukey’s test for multiple comparisons used; * = p<0.05, *** = p<0.001)  
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Chapter 4  
4 Discussion 
Renal transplantation is considered to be the most effective renal replacement therapy in 
ESRD patients. Due to the disparity between the organ demand and supply, the use of 
marginal donors (such as DCD donors) has become acceptable. However, the DCD grafts 
experience prolonged IRI and are more susceptible to failure and delayed graft function. 
Thus, finding ways to mitigate IRI in these grafts has become the prime focus of the 
transplant community.  
Our lab has previously shown the protective effects of supplementation with exogenous 
H2S on graft function after either prolonged warm ischemia or cold storage.
90,112
 
However, the murine model of renal transplantation used in this study is the first of its 
kind to use a combination of both warm ischemia and cold storage and mimics the clinical 
model of a DCD transplant. The DCD murine model used in this study showed improved 
graft function and survival rate in the recipients with concurrent exogenous (NaHS) and 
endogenous (D-cysteine/3MST pathway) H2S supplementation. This is in accordance 
with other renal IRI studies performed in mice or rats showing protective effects of either 
exogenous H2S addition involving 30 minutes to 1 hour of pedicle clamping (warm 
ischemia)
84,90,112
 or showing how endogenous H2S also helps mitigate effects of IRI in 
renal models.
113
 L-cysteine is a widely used substrate for H2S production endogenously 
through the CBS and CSE enzymatic pathways. It generally overshadows the role played 
by D-cysteine in H2S production internally. However, a recent study by Shibuya and 
Kimura (2013) showed that D-cysteine diminishes impact of IRI more effectively than L-
cysteine because of its 80-fold greater H2S producing activity in the kidney.
105
 This is the 
reason why I chose to incorporate a combination of D-cysteine and exogenous H2S 
supplementation in our experimental study. 
H2S supplementation in this model of prolonged warm ischemia and cold storage 
followed by subsequent renal transplantation led to increased survival rate, faster 
recovery of graft function and less renal injury in treatment group rats. By post-operative 
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day 10, the treatment group’s serum creatinine was almost equivalent to the baseline 
sham levels while it took almost 20 days for the untreated group to reach the baseline 
levels. This indicates prevention of delayed graft function in the recipients that could help 
eliminate the need for dialysis after the first week of transplantation. The urine 
osmolality, on the other hand, was lower for both the untreated and treatment groups in 
comparison to the sham group rats. Decreased urine osmolality is a marker of either 
impaired renal function or diuresis in the transplant recipients as another study has 
reported diuresis in the transplant recipients in an IRI model.
112
 However, further analysis 
such as the glomerular filtration rate along with the concentration of various ions (like 
sodium and potassium) in urine and blood serum can help elucidate the actual cause of 
decrease in urine osmolality for the subjects in our study.  
One of the ways in which our study is different from others is the length of the 
experimental period (30 days). This helped us to look at the long-term effects rather than 
limiting it to earlier time points of 2-weeks or less. Tissue analysis indicated comparable 
amounts of acute tubular necrosis and apoptosis among the untreated and treatment group 
rats. Other studies have observed comparable increases in apoptosis and necrosis in non-
transplantation in-vivo IRI models involving clamping induced warm ischemia in renal 
tissue
84
 and myocardium. 
89,104
 
For studying the IRI mechanism at a cellular level, the proximal tubular epithelial kidney 
cells are considered to be the prime choice. The reason for this preference stems from the 
fact that maximum I/R injury is observed in the epithelial cells of the proximal tubular 
region in the nephrons depicted by the loss of apical brush border.
114
 One can argue that 
the in-vitro experiments are limited in their ability to exactly replicate the internal 
physiologic environment as experienced by the cells during in-vivo IRI models, but they 
are still considered to be the best way to tease apart the cellular signaling pathways and 
mechanisms.  
In-vitro studies have shown that the hypoxia-reoxygenation model mimics a similar kind 
of injury as sustained by the kidney during in-vivo IRI. However, different studies vary in 
the methods of inducing hypoxia that can involve the use of chemicals (mitochondrial 
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electron transport chain inhibitors like rotenone, antimycin A and sodium azide), 
enzymatic pathway (Glucose oxidase-GOX and Catalase-CAT; generally called the 
GOX/CAT system) or a hypoxia chamber (varying concentrations of oxygen - 0.5% to 
1% and carbon dioxide – 5% - 20%).114–117 For this study, I used a precisely regulated 
hypoxia chamber (as described in methods) to induce the hypoxic injury at 1% oxygen for 
12 hours and maintaining 37ºC temperature followed by 20-24 hours of reoxygenation. 
The time interval for hypoxia was based on a number of optimization experiments with 
varying time periods as was described in the results section.  
Our in-vitro hypoxia-reoxygenation experiments corroborated results obtained in our in-
vivo DCD murine model. The addition of slow releasing H2S donor (GYY4137) was able 
to rescue the cells from in-vitro hypoxia-reoxygenation injury as observed by increased 
percentage of cell viability and decreased percentage of necrosis and late apoptosis in the 
specific cell samples containing 50μM GYY4137. Similar protective effects of H2S 
supplementation have been observed in other in-vitro studies involving the use of NaHS 
in either chemically induced hypoxia in human skin keratinocytes or hypoxia induced by 
chamber in human umbilical vein endothelial cells (HUVECs).
118,119
 However, these 
effects have not been tested in kidney cell lines. A study performed many years ago by 
Wiegele et al. (1998) showed that the mechanisms of cell death happening from ATP 
depletion involved apoptosis and necrosis. In their study, apoptosis was observed only at 
early stages and only in a small proportion of cells while the necrotic pathway was the 
major culprit of cell death especially with longer periods (more than 8 hours) of ATP 
depletion.
117
 A similar trend was observed in our in-vitro model whereby the prolonged 
hypoxic conditions triggered the necrotic cell death.  
One challenge was to assess early apoptotic cells in-vitro. Studies by Bursch et al. in 1990 
noted that the time span from initiation to completion of apoptosis could be as short as 2-
3 hours.
120,121
 Hence, by the time the cells are analyzed, there is a high possibility that the 
early apoptotic cells become late apoptotic or necroptotic. This explains why early 
apoptosis might have gone un-detected in our in-vitro experiments. On the other hand, 
contradictory findings have been reported in literature in regards to apoptosis versus 
necrosis contribution to cell death. One study of cutaneous tissue transplantation has 
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reported increased apoptosis along with necrosis following IRI
119
 and the same was 
observed in our in-vivo model as well. However, it must be noted that IRI based in-vitro 
studies of hypoxia-reoxygenation look at longer time points and generally report the late 
apoptotic cells.  
Although there might be differences in the extent of apoptosis and necrosis observed after 
IRI, the cellular pathways and pathophysiology associated with the two processes is very 
similar ultimately resulting in cell death. Both the processes stem from increased ROS 
and mitochondrial membrane depolarization. Our in-vitro experiments showed a trend of 
reduction in the percentage of cells with ROS in cell samples supplemented with H2S 
donor. Despite the fact that the amount of ROS present in the treatment group was not 
significantly lower than the untreated group, even a slight decline in ROS could 
potentially prove beneficial for rescuing the cells considering the negative impact ROS 
has on mitochondria and the cell as a whole. The use of stain DHR 123 for detection of 
ROS has been well established in literature as it has been previously used for studying 
oxidative burst in human granulocytes.
122
 One drawback for using this stain is its higher 
sensitivity to H2O2 in comparison to other reactive molecules resulting from IRI such as 
superoxides and per-oxy-nitrites. Superoxide constitutes majority of the ROS and is 
formed mainly in the mitochondria where it then reacts with the mitochondrial enzymes 
to form H2O2.
123,124
 
The mitochondrial apoptotic pathway is one of the major contributors of apoptotic cell 
death while the other pathway that feeds apoptosis is the signaling by death receptors. The 
mitochondrial pathway involves the crucial process of mitochondrial outer membrane 
permeabilization (MOMP).
102,125
 One of the ways in which this is achieved is the 
formation of the permeability transition pore that leads to a change in the mitochondrial 
membrane potential due to equilibration of ions across the membrane.
126
 This eventually 
leads to swelling of the mitochondria followed by breaking of the outer membrane 
producing MOMP.
125
 In this study, it was observed that the addition of H2S donor in 
adequate amounts resulted in a decline in percentage of cells with depolarized 
mitochondrial membrane. This indicates that H2S hinders the MOMP by preventing the 
permeability transition pore from causing the leakage of ions and thereby impeding 
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depolarization of the mitochondrial membrane. However, this study did not explore if 
H2S actually blocks these pores or inhibits the formation of these pores to prevent 
depolarization.   
The second mechanism for MOMP is mediated by the members of the Bcl-2 protein 
family. It is widely accepted that certain members of the Bcl-2 family are pro-apoptotic 
(such as Bax, Bak or Bid) while others act as anti-apoptotic molecules (such as Bcl-2, 
Mcl-1).
46
 The Bcl-2 is the prototype member of this family of proteins and all members 
contain at least one Bcl-2 homology (BH) region. The mRNA expression of these 
proteins was assessed via qRT-PCR in both the in-vivo and in-vitro samples.  The in-vivo 
samples showed up regulation of apoptotic proteins such as caspase-3 and Bax in the rats 
from untreated group. Still other pro-apoptotic (Bid) and inflammatory (TNF-α) 
molecules showed similar expression as the baseline sham levels. However, the same 
apoptotic and inflammatory markers were highly down regulated in the treatment group 
rats except the Bax protein that was being expressed at baseline levels. On the contrary, 
the pro-apoptotic proteins depicted a trend of down regulation in both the treated as well 
as untreated cell samples in the in-vitro experiments. 
Previous studies have shown a link between Bax expression and induction of apoptosis in 
cells.
127
 Bax and Bid are generally present in the cytosol of the cells. Upon initiation of 
apoptotic signaling pathways, these molecules help in inducing MOMP and the eventual 
leakage of cytochrome c and other proteins from the mitochondria that result in apoptosis 
in the cells.
125,128
 However, these molecules are not solely responsible for MMPT as a 
study by De Marchi et al. showed that blocking the pro-apoptotic proteins like the 
Bax/Bid did not completely inhibit the depolarization of the mitochondrial membrane in 
the cells.
129
 They also showed that other mechanisms like high intracellular 
concentrations of Ca
+2
 could still result in MMPT in absence of Bax/Bid. This explains 
some differences observed in the expression of pro-apoptotic proteins in the in-vivo and 
in-vitro models in our study since the Bax was not upregulated in the LLC-PK1 cells 
undergoing IRI but still apoptosis was observed in these samples.  
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One anomaly observed in our in-vivo experiments was the up regulation of Bcl-2 in both 
the untreated and the treatment group rats while our in-vitro hypoxia-reoxygenation 
model showed a significant up regulation in the mRNA expression of anti apoptotic 
proteins Mcl-1and Bcl-2 only in the cell samples treated with 50μM GYY4137. There 
was also a significant decrease detected in the expression of injury marker EDN-1 in the 
same cell samples that were supplemented with H2S donor in comparison to the untreated 
cell samples. One of the reasons that can help explain this conflict between the results 
from in-vivo and in-vitro experiments is the time point at which the data were collected. 
The graft tissues used for qRT-PCR were collected from the renal transplant recipient rats 
on post-operative day 3 while the mRNA was collected from the LLC-PK1 cells right 
after experiencing 12 hours of warm hypoxia followed by 15 minutes of reoxygenation.  
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Chapter 5  
5 Future Directions 
Our in-vivo murine model, although first of its kind to mimic DCD renal transplantation, 
studies the combined effect of increasing endogenous H2S production prior to ischemia 
along with exogenous H2S supplementation during the cold storage phase of the graft. It 
would be interesting to observe the two conditions separately and to see if the effects of 
endogenous and exogenous H2S are synergic in nature. Further, the verification of various 
apoptotic or anti-apoptotic proteins in the tissue samples using western blots might help 
solidify the results obtained through mRNA analysis.   
The results from in-vitro experiments did not show a large number of early apoptotic cells 
after hypoxic injury and 24 hours of reoxygenation. However, the ROS and mitochondrial 
membrane potential analysis that was performed after smaller periods or no 
reoxygenation showed some differences between the untreated and treatment group 
samples. It would be intriguing to measure percentage of apoptotic cells following smaller 
periods of reoxygenation after the hypoxic injury. Maybe, a time-course experiment could 
help shed some light on this phenomenon. In addition, to better understand the 
mechanism of H2S action in mitochondrial apoptotic pathway, the leakage of 
mitochondrial cytochrome c into the cytoplasm could be studied. This can be done by 
separating the mitochondrial and cytosolic contents and then measuring the concentration 
of cytochrome c in each separately. An increase in the ratio of the mitochondrial to 
cytoplasmic cytochrome c in treated samples would indicate a definitive role of H2S in 
preventing MOMP.   
Our study focused on only one H2S releasing donor molecule (GYY4137). However, it 
would be fascinating to see the effect of other H2S donor molecules that release H2S in a 
targeted way or stimulate endogenous production of H2S. One such recently discovered 
molecule is AP39 that is a targeted mitochondrial H2S donor. Since one of the major 
apoptotic pathways and cell death mechanism involves the mitochondria, this molecule 
might prove to be the ideal candidate for future studies.    
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Chapter 6 
6 Conclusion and Significance 
Our study is the first ever study looking at the use of H2S in a clinically relevant murine 
model of DCD renal transplantation. Other studies that demonstrate the protective effects 
of H2S against IRI do not involve the transplantation of the organ experiencing IRI into 
the recipient. The few exceptional studies that do involve renal transplantation fail to 
investigate the combined effect of warm ischemia and prolonged cold storage. In our 
study, H2S supplementation resulted in increased survival and improved renal graft 
function along with a significant decrease in histological injury among the treatment 
group rats. The in-vitro model also recapitulated the protective role of slow releasing H2S 
donor molecule (GYY4137) on the proximal tubular porcine kidney epithelial cells (LLC-
PK1) as shown by the reduction in depolarization of the mitochondrial membrane, the 
ROS and the increased cell viability in treated cell samples. It also exemplifies an 
important role played by the mitochondria in cell death caused by the hypoxia-
reoxygenation injury as depicted by up regulation of the mitochondrial associated anti-
apoptotic marker Bcl-2, Mcl-1 and decreased expression of pro-apoptosis related genes 
such as Bax and Bid.  
The results from this study illustrate the clinical significance of H2S mediated protective 
pathways in IRI and the future of DCD transplants. Considering the short half-life of H2S 
and its depletion by the time of transplantation in the recipients, it should be feasible to 
make minimal changes to the current clinical protocol and adopt the use of H2S into 
clinical practice. This transition would not only help to reduce the extent of IRI and 
delayed graft function experienced by the DCD organs but may also help increase the 
pool of donors that are deemed suitable for renal transplantation.    
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Appendices  
Appendix A: Preliminary data showing graft recovery following renal 
transplantation with grafts that had experienced IRI. 
 
Serum creatinine levels of renal transplant recipients after receiving donor kidneys that 
were clamped for 20 minutes and underwent a cold ischemic period of 18 hours in UW 
solution only (untreated group), D-cysteine pre-op and UW solution plus 150μM NaHS 
(treatment group) as well as sham-operated rats. (Mean values are shown, n=1) 
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Appendix B: Ethics approval form for in-vivo experiments 
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